Combination drug products are complex to both develop and to manage from a compliance perspective. This presentation discusses five critical areas of combination drug compliance including:
- What is 21 CFR Part 4?
- FDA’s Office of Combination Products
- Legacy Combination Drug Products – Compliance with 21 CFR Part 4
- Product Stability Studies Strategy
- Streamlined Approach for Review and Approval of Some Combination Products
